The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New on provides more data that treating certain lymphoma patients with an costly drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly rise life span, raising questions about whether it's worth taking. People with lymphoma who are light of maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, foreman of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The look at involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a span that refers to cancers of the immune system.
Though it can be fatal, most nation live for at least 10 years after diagnosis. There has been debate over whether people with the disease should convoy Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical cast that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not. All formerly had taken the drug right after receiving chemotherapy.
In the next three years, the mull over found, people taking the drug took longer, on average, to lay open symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't pirate the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Showing posts with label lymphoma. Show all posts
Showing posts with label lymphoma. Show all posts
Thursday 29 November 2018
Tuesday 15 May 2018
A Promising Way To Treat Specific Lymphoma
A Promising Way To Treat Specific Lymphoma.
Researchers have identified a gene deviant that may proposition a target for new treatments for a type of lymphoma. The pair found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as massive B cell lymphoma. The MYD88 gene encodes a protein that is crucial for healthy immune response to invading microorganisms.
The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of pernicious cells. A subgroup of the large B cell lymphoma that has a dismally enervated cure rate - known as the activated B cell-like (ABC) subtype - appears exceptionally susceptible to the gene.
Researchers have identified a gene deviant that may proposition a target for new treatments for a type of lymphoma. The pair found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as massive B cell lymphoma. The MYD88 gene encodes a protein that is crucial for healthy immune response to invading microorganisms.
The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of pernicious cells. A subgroup of the large B cell lymphoma that has a dismally enervated cure rate - known as the activated B cell-like (ABC) subtype - appears exceptionally susceptible to the gene.
Tuesday 29 August 2017
New Research In The Treatment Of Cancer Of Immune System
New Research In The Treatment Of Cancer Of Immune System.
New examination provides more sign that treating certain lymphoma patients with an valuable drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's worth taking. People with lymphoma who are making allowance for maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, governor of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The library involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a period that refers to cancers of the immune system.
Though it can be fatal, most ladies and gentlemen live for at least 10 years after diagnosis. There has been debate over whether people with the disease should escort Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical companions that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All in days gone by had taken the drug right after receiving chemotherapy.
In the next three years, the swat found, people taking the drug took longer, on average, to emerge symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't ingest the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New examination provides more sign that treating certain lymphoma patients with an valuable drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's worth taking. People with lymphoma who are making allowance for maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, governor of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The library involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a period that refers to cancers of the immune system.
Though it can be fatal, most ladies and gentlemen live for at least 10 years after diagnosis. There has been debate over whether people with the disease should escort Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical companions that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All in days gone by had taken the drug right after receiving chemotherapy.
In the next three years, the swat found, people taking the drug took longer, on average, to emerge symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't ingest the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Tuesday 14 March 2017
Many Survivors Of Lymphoma Did Not Receive A Recommendation To Take Further Tests For Other Types Of Cancer
Many Survivors Of Lymphoma Did Not Receive A Recommendation To Take Further Tests For Other Types Of Cancer.
Many Hodgkin lymphoma survivors don't pull down recommended consolidation screening tests for other cancers, a supplementary inquiry finds. "Most Hodgkin lymphoma patients are cured, but they can be at risk many years later of developing unessential cancers or other late effects of their initial treatment. This is why value of follow-up care post-treatment is so important," principal investigator Dr David Hodgson, a emanation oncologist at the Princess Margaret Hospital Cancer Program in Toronto, Canada, said in a University Health Network word release.
He and his colleagues followed 2071 survivors for up to 15 years after Hodgkin lymphoma diagnosis and found that 62,5 percent were not screened for colorectal cancer, 32,3 percent were not screened for chest cancer, and 19,9 percent were not screened for cervical cancer. "Our results exhibit that the optimal backup care did not happen, even though most patients had visits with both a primary care provider and an oncologist in years two through five.
Many Hodgkin lymphoma survivors don't pull down recommended consolidation screening tests for other cancers, a supplementary inquiry finds. "Most Hodgkin lymphoma patients are cured, but they can be at risk many years later of developing unessential cancers or other late effects of their initial treatment. This is why value of follow-up care post-treatment is so important," principal investigator Dr David Hodgson, a emanation oncologist at the Princess Margaret Hospital Cancer Program in Toronto, Canada, said in a University Health Network word release.
He and his colleagues followed 2071 survivors for up to 15 years after Hodgkin lymphoma diagnosis and found that 62,5 percent were not screened for colorectal cancer, 32,3 percent were not screened for chest cancer, and 19,9 percent were not screened for cervical cancer. "Our results exhibit that the optimal backup care did not happen, even though most patients had visits with both a primary care provider and an oncologist in years two through five.
Subscribe to:
Posts (Atom)